<DOC>
	<DOCNO>NCT01194570</DOCNO>
	<brief_summary>This randomize , parallel group , double-blind , placebo control study evaluate efficacy safety ocrelizumab participant primary progressive multiple sclerosis . Eligible participant randomize 2 : 1 receive either ocrelizumab placebo . The blinded treatment period least 120 week , follow Open Label Extension ( OLE ) treatment participant group opinion investigator could benefit newly initiate ocrelizumab treatment . Unless terminate early , participant continue treatment open-label ocrelizumab last participant enter OLE phase reach 4 year open-label ocrelizumab treatment .</brief_summary>
	<brief_title>A Study Ocrelizumab Participants With Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Diagnosis primary progressive multiple sclerosis ( accord revise McDonald criterion ) EDSS screen 3 6.5 point Disease duration onset MS symptom less ( &lt; ) 15 year EDSS great ( &gt; ) 5.0 ; &lt; 10 year EDSS great equal ( &gt; /= ) 5.0 Sexually active male female participant reproductive potential must use two method contraception throughout study treatment phase 48 week last dose History relapse remit MS , secondary progressive , progressive relapse MS screen Inability complete MRI ( contraindication MRI ) Known presence neurologic disorder Known active infection history presence recurrent chronic infection History cancer , include solid tumor hematological malignancy ( except basal cell , situ squamous cell carcinoma skin situ carcinoma cervix excise resolve ) Previous treatment Bcell target therapy ( e.g . rituximab , ocrelizumab , atacicept , belimumab , ofatumumab ) Any previous treatment lymphocyte traffic blocker , alemtuzumab , anticluster differentiation 4 ( CD4 ) , cladribine , cyclophosphamide , mitoxantrone , azathioprine , mycophenolate mofetil , cyclosporine , methotrexate , total body irradiation , bone marrow transplantation Any concomitant disease may require chronic treatment systemic corticosteroid immunosuppressant course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>